Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGYN-trial
2023-504945-30-00Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in bladder cancer comparing Intravesical gemcitabine with Intravesical mitomycin (2 arms). Primary endpoint: Recurrence-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
gemcitabinemitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2023-504945-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504945-30-00.